SBIR-STTR Award

Intensity coded DNA sequencing
Award last edited on: 6/20/02

Sponsored Program
SBIR
Awarding Agency
NIH : NCHGR
Total Award Amount
$50,000
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Carl W Fuller

Company Information

United States Biochemical Corporation

26111 Miles Road
Cleveland, OH 44128
   (216) 765-5000
   N/A
   N/A
Location: Single
Congr. District: 11
County: 

Phase I

Contract Number: 1R43HG000191-01A1
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1991
Phase I Amount
$50,000
DNA sequencing typically requires four parallel reactions run on four parallel lanes of an electrophoresis gel. Together with gel interpretation, this represents most of the labor once the template DNA is prepared. We will develop a simplified DNA sequencing method using a single reaction and a single lane of a gel. The sequence information will be encoded in the intensities of the bands. This Intensity-Encoded Sequencing (IES) method takes advantage of three recent advances currently being marketed and developed at United States Biochemical Corporation (USB). One is Sequence Version 2.0, a patented enzyme which generates exceptional sequencing results. The second is the use of Mn2+ and inorganic pyrophosphatase with Sequenase. These make chain termination sequence-independent, giving uniform band intensities. Thus, all four dideoxy-nucleotides can be included at different concentrations in a single reaction; band intensity depends on the concentration, so the nucleotide can be determined from the band intensity. Finally, the gels are read using an inexpensive precision optical scanner to be introduced by USB in early 1991. IES is simple and inexpensive enough to be run in any laboratory that does sequencing. commercial products will include a reagent kit for running IES reactions and software to interpret gels.Awardee's statement of the potential commercial applications of the research:Direct commercial products will include reagents and kits for DNA sequencing as well as instruments and software for reading sequences. Commercial applications for DNA sequencing will include organism identification, diagnostics and medical research such as the Human Genome Mapping and Sequencing Project.National Center for Human Genome Research (NCHGR)

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----